Injection burden 12 injections most days Best for Independent dose control Cycle driver Compound-specific phasing BPC-157 Loading 250500 mcg, daily Frequency Daily Maintenance 250 mcg, daily Route SubQ TB-500 Loading 2.05.0 mg, 2x/week Frequency 2x/week (loading), 12x/week (maintenance) Maintenance 2.0 mg, 12x/week Route SubQ Example Weekly Schedule (Loading Phase) Monday BPC-157 500 mcg SubQ + TB-500 2.5 mg SubQ Tuesday BPC-157 500 mcg SubQ Wednesday BPC-157 500 mcg SubQ Thursday BPC-157 500 mcg SubQ + TB-500 2.5 mg SubQ Friday BPC-157 500 mcg SubQ Saturday BPC-157 500 mcg SubQ Sunday BPC-157 500 mcg SubQ Use separate sterile syringes for separate-vial draws
The head-to-head data is equally decisive
FOXO4-DRI is supplied in lyophilized form strictly for controlled laboratory research applications
Patients who have highly reactive or barrier-impaired skin should introduce any new GHK-Cu copper peptide product gradually and avoid combining it with strong exfoliants, retinoids, or aggressive in-office treatments
Responses occurred regardless of TROP2 expression [42]
At 50 mg in 2 mL, a 5 mg dose is 20 units on a U-100 syringe
